WALDWLOW SIGNALFINANCIAL10-Q

WALDW's quarterly filing shows routine SPAC operational updates with modest cash position decline and expanded disclosure on warrant liabilities and forward purchase agreements.

The filing reflects typical SPAC activity during the target identification phase, with updated financial statement periods and enhanced disclosures around warrant accounting and forward purchase commitments. The language changes indicate normal quarterly reporting progression with more detailed explanations of the company's capital structure and business combination search process.

Comparing 2022-05-16 vs 2021-11-18View on EDGAR →
FINANCIAL ANALYSIS

The company's cash position declined modestly from $1.5M to $1.1M, representing normal operating expenses during the target search phase. Current assets similarly decreased from $1.7M to $1.3M, reflecting ongoing operational costs typical for SPACs. The overall financial picture shows a stable but gradually declining cash position as expected for a SPAC actively seeking acquisition targets.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-27.6%
$1.5M→$1.1M

Cash decreased 27.6% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-26.7%
$1.7M→$1.3M

Current assets declined 26.7% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2022-05-16
PRIOR — 2021-11-18
ADDED
7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Financial Statements 1 Condensed Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021 1 Unaudited Condensed Statements of Operations for the Three Months Ended March 31, 2022 and March 31, 2021 2 Unaudited Condensed Statements of Changes in Shareholders Deficit for the Three Months Ended March 31, 2022 and March 31, 2021 3 Unaudited Condensed Statements of Cash Flows for the Three Months Ended March 31, 2022 and March 31, 2021 4 Notes to Condensed Financial Statements 5 Item 2.
All activity since January 12, 2021 relates to the Company s formation and the initial public offering (the Initial Public Offering ) and identifying a target or targets for a Business Combination, as described below.
The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering and change in fair value of its warrant and forward purchase agreement liabilities.
Of the total transaction costs, $ 719,201 was reclassified as non-operating expense in the statements of operations with the rest of the offering costs charged to shareholders deficit.
+7 more — sign up free →
REMOVED
Financial Statements Condensed Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 (audited) 1 Condensed Statements of Operations for the three and nine months ended September 30, 2021 (unaudited) 2 Condensed Statements of Changes in Shareholders Deficit for the three and nine months ended September 30, 2021 (unaudited) 3 Condensed Statement of Cash Flows for the nine months ended September 30, 2021 (unaudited) 4 Notes to Unaudited Condensed Financial Statements 5 Item 2.
All activity since January 12, 2021 relates to the Company s formation and the initial public offering (the Initial Public Offering ), as described below.
The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering.
Of the total transaction costs, $ 719,201 was reclassified as non-operating expense in the condensed statement of operations with the rest of the offering costs charged to shareholders equity.
Liquidity As of September 30, 2021, the Company had cash in an operating bank account, outside of the Trust Account, of $335,058 available for working capital needs.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →